Dr. Albensi completed his PhD in Neuroscience at the University of Utah’s School of Medicine in 1995. He
obtained advanced training as a Postdoctoral Fellow at the Georgetown Institute of Cognitive and Computational
Sciences (GICCS) at Georgetown University Medical Center where he worked with a high field MRI system for
assessing brain trauma and its effect on hippocampal structure and physiology. Thereafter he trained under Dr. Mark
Mattson as a Postdoctoral Scholar at the Sanders-Brown Center on Aging at the University of Kentucky’s Medical
School and studied the involvement of NF-kB in synaptic plasticity. Subsequently, he participated in clinical trials
research at Pfizer, Inc. in Ann Arbor, Michigan. Currently he holds the Honourable Douglas Everett, Patricia Everett
and the Royal Canadian Properties Endowment Fund Chair and is an Associate Professor of Pharmacology and
Therapeutics at the University of Manitoba, Winnipeg, Canada. In addition, he is an Adjunct Professor of Electrical
and Computer Engineering at this same school and a Principal Investigator in the Division of Neurodegenerative
Disorders at the St. Boniface Research Centre. He is also a Research Affiliate for the University of Manitoba’s
Centre on Aging and a Scientist at the Manitoba Institute for Child Health (MICH). He has published more than 100
articles that include peer-reviewed experimental papers, invited book chapters and reviews, abstracts, and other CNS
relevant manuscripts on synaptic plasticity, memory, and neuronal excitability. In addition he has been a member of
several grant review panels around the world, including the NIH, CIHR, Alzheimer’s Society of Canada,
Alzheimer’s Association (USA), Wellcome Trust, American Institute of Biological Sciences, and the U.S. Civilian
Research & Development Foundation. He is also on the editorial board of CNS and Neurological Disorders - Drug
Targets. He is married and lives in Winnipeg, Canada with his four daughters.
